Locoregional therapy and systemic cetuximab to treat colorectal liver metastases

World Journal of Gastrointestinal Oncology

Volumn 7, Issue 6, 2015, Pages 47-54

  Fiorentini, Giammaria ^a   Sarti, Donatella ^a   Giordani, Paolo ^a   Graziano, Francesco ^a   Catalano, Vincenzo ^a   Aliberti, Camillo ^b   Coschiera, Paolo ^c   Mulazzani, Luca ^c   Tilli, Massimo ^d   Gonzalez, Alfonso Marqués ^e   Marcos, Raul García ^e   Mugnoz, Fernando Gómez ^f   Cantore, Maurizio ^g   Ricci, Stefano ^h   Mambrini, Andrea ⁱ  

^a SAN SALVATORE HOSPITAL   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c Azienda Ospedaliera Ospedali Riuniti Marche Nord   (Italy)

^d Delta Hospital   (Italy)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g CARLO POMA HOSPITAL   (Italy)

^h INRCA   (Italy)

ⁱ Carrara Hospital   (Italy)

Author keywords

Cetuximab; Chemoembolization; Colon rectal tumor; Hepatic metastases; Irinotecan; Irinotecan loaded drug eluting beads

Indexed keywords

EID: 84992131289     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/wjgo.v7.i6.47     Document Type: Article

References (48)

1. 1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403 [PMID: 23485231 DOI: 10.1016/j.ejca.2012.12.027]
2. 2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-488 [PMID: 15718248 DOI: 10.1093/annonc/mdi098]
3. 3. O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-1425 [PMID: 15467030]
4. 4. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghémard O, Levi F, Bismuth H. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-657; discussion 657-658 [PMID: 15383792 DOI: 10.1097/01.sla.0000141198.92114.f6]
5. 5. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214 [PMID: 15051767 DOI: 10.1200/JCO.2004.11.037]
6. 6. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237 [PMID: 14657227 DOI: 10.1200/JCO.2004.05.113]
7. 7. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914 [PMID: 11006366 DOI: 10.1056/NEJM200009283431302]
8. 8. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30 [PMID: 14665611 DOI: 10.1200/JCO.2004.09.046]
9. 9. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-2069 [PMID: 12775730 DOI: 10.1200/JCO.2003.11.126]
10. 10. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676 [PMID: 17470860 DOI: 10.1200/JCO.2006.09.0928]
11. 11. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019 [PMID: 18421054 DOI: 10.1200/JCO.2007.14.9930]
12. 12. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417 [PMID: 19339720 DOI: 10.1056/NEJMoa0805019]
13. 13. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671 [PMID: 19114683 DOI: 10.1200/JCO.2008.20.8397]
14. 14. Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, Zwiebel J, Kaplan RS. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006; 24: 3354-3360 [PMID: 16849749 DOI: 10.1200/JCO.2005.05.1573]
15. 15. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995; 95: 1897-1905 [PMID: 7706497 DOI: 10.1172/JCI117871]
16. 16. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345 [PMID: 15269313 DOI: 10.1056/NEJMoa033025]
17. 17. Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, Rilling WS, Geschwind JF, Salem R, Vedantham S, Cardella JF, Soulen MC. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2007; 18: 1469-1478 [PMID: 18057279 DOI: 10.1016/j.jvir.2007.08.027]
18. 18. Tang Y, Taylor RR, Gonzalez MV, Lewis AL, Stratford PW. Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases. J Control Release 2006; 116: e55-e56 [PMID: 17718969 DOI: 10.1016/j.jconrel.2006.09.047]
19. 19. Taylor RR, Tang Y, Gonzalez MV, Stratford PW, Lewis AL. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 2007; 30: 7-14 [PMID: 17030118 DOI: 10.1016/j.ejps.2006.09.002]
20. 20. Fiorentini G. A new tool to enhance the efficacy of chemoe-mbolization to treat primary and metastatic hepatic tumors. Expert Opin Drug Deliv 2011; 8: 409-413 [PMID: 21413909 DOI: 10.1517/17425247.2011.565327]
21. 21. Lewis AL, Holden RR. DC Bead embolic drug-eluting bead: clinical application in the locoregional treatment of tumours. Expert Opin Drug Deliv 2011; 8: 153-169 [PMID: 21222553 DOI: 10.151 7/17425247.2011.545388]
22. 22. Aliberti C, Tilli M, Benea G, Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res 2006; 26: 3793-3795 [PMID: 17094403]
23. 23. Fiorentini G, Aliberti C, Turrisi G, Del Conte A, Rossi S, Benea G, Giovanis P. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo 2007; 21: 1085-1091 [PMID: 18210761]
24. 24. Martin RC, Howard J, Tomalty D, Robbins K, Padr R, Bosnjakovic PM, Tatum C. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Intervent Radiol 2010; 33: 960-966 [PMID: 20661569 DOI: 10.1007/s00270-010-9937-4]
25. 25. Aliberti C, Fiorentini G, Muzzio PC, Pomerri F, Tilli M, Dallara S, Benea G. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res 2011; 31: 4581-4587 [PMID: 22199334]
26. 26. Kettenbach J, Stadler A, Katzler IV, Schernthaner R, Blum M, Lammer J, Rand T. Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 2008; 31: 468-476 [PMID: 18228095 DOI: 10.1007/s00270-007-9280-6]
27. 27. Narayanan G, Barbery K, Suthar R, Guerrero G, Arora G. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. Anticancer Res 2013; 33: 2077-2083 [PMID: 23645758 DOI: 10.1016/j.jvir.2013.01.030]
28. 28. Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, Mambrini A, Montagnani F, Alessandroni P, Catalano V, Coschiera P. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32: 1387-1395 [PMID: 22493375]
29. 29. Gaur SK, Friese JL, Sadow CA, Ayyagari R, Binkert CA, Schenker MP, Kulke M, Baum R. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol 2011; 34: 566-572 [PMID: 21431978 DOI: 10.1007/s00270-011-0122-1]
30. 30. Fiorentini G, Aliberti C, Benea G, Montagnani F, Mambrini A, Ballardini PL, Cantore M. TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects. Hepatogastroenterology 2008; 55: 2077-2082 [PMID: 19260480]
31. 31. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216 [PMID: 10655437 DOI: 10.1093/jnci/92.3.205]
32. 32. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430 [PMID: 11592607 DOI: 10.1016/S0168-8278(01)00130-1]
33. 33. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-1759 [PMID: 17470865 DOI: 10.1200/JCO.2006.07.3049]
34. 34. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19: 508-515 [PMID: 17998284 DOI: 10.1093/annonc/mdm496]
35. 35. Wieser M, Sauerland S, Arnold D, Schmiegel W, Reinacher-Schick Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials. BMC Cancer 2010; 10: 309 [PMID: 20565923 DOI: 10.1186/1471-2407-10-309]
36. 36. Inoue Y, Hiro J, Toiyama Y, Tanaka K, Mohri Y, Kusunoki M. Optimal use of current chemotherapy in multimodality therapy for advanced colorectal cancer. Oncol Lett 2012; 3: 363-368 [PMID: 22740912]
37. 37. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003; 14 Suppl 2: ii13-ii16 [PMID: 12810452 DOI: 10.1093/annonc/mdg731]
38. 38. Cohen AD, Kemeny NE. An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 2003; 8: 553-566 [PMID: 14657534 DOI: 10.1634/theoncologist.8-6-553]
39. 39. Eichler K, Zangos S, Mack MG, Hammerstingl R, Gruber-Rouh T, Gallus C, Vogl TJ. First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). Int J Oncol 2012; 41: 1213-1220 [PMID: 22842404 DOI: 10.3892/ijo.2012.1572]
40. 40. Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 2006; 17: 217-223 [PMID: 16517767 DOI: 10.1097/01.RVI.0000196277.76812.A3]
41. 41. Herrmann KA, Waggershauser T, Sittek H, Reiser MF. Liver intraarterial chemotherapy: use of the femoral artery for percutaneous implantation of catheter-port systems. Radiology 2000; 215: 294-299 [PMID: 10751501]
42. 42. Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R, Zangos S. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 2009; 250: 281-289 [PMID: 19092099 DOI: 10.1148/radiol.2501080295]
43. 43. Martin RC, Joshi J, Robbins K, Tomalty D, Bosnjakovik P, Derner M, Padr R, Rocek M, Scupchenko A, Tatum C. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 2011; 18: 192-198 [PMID: 20740319 DOI: 10.1245/s10434-010-1288-5]
44. 44. Bower M, Metzger T, Robbins K, Tomalty D, Válek V, Boudný J, Andrasina T, Tatum C, Martin RC. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. HPB s 2010; 12: 31-36 [PMID: 20495642 DOI: 10.1111/j.1477-2574.2009.00117.x]
45. 45. Fiorentini G, Montagnani F, Tilli M, Mambrini A, Benea G. Trans-arterial chemoembolisation of metastatic colorectal carcinoma (mCRC) to the liver adopting polyvinylalcohol microspheres loaded with irinotecan (DEBIRI) compared to FOLFIRI (CT): evaluation at two years of a phase III clinical trial. Ann Oncol 2010; 21
46. 46. Kemeny MM, Adak S, Gray B, Macdonald JS, Smith T, Lipsitz S, Sigurdson ER, O’Dwyer PJ, Benson AB. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy–an intergroup study. J Clin Oncol 2002; 20: 1499-1505 [PMID: 11896097 DOI: 10.1200/JCO.20.6.1499]
47. 47. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-1169 [PMID: 17375050]
48. 48. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6: 519-527 [PMID: 19636327 DOI: 10.1038/nrclinonc.2009.111]